Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, People's Republic of China.
Clin Transl Oncol. 2013 Feb;15(2):139-45. doi: 10.1007/s12094-012-0900-5. Epub 2012 Jul 19.
Matrix metalloproteinase (MMP)-14 and MMP-19 have been demonstrated to play an important role in the development of human gliomas. However, their prognostic values are not clear. The aim of this study was to investigate whether co-expression of MMP-14 and MMP-19 has prognostic relevance in human gliomas.
Immunohistochemistry and western blot were used to investigate the expression of MMP-14 and MMP-19 proteins in 128 patients with gliomas.
The expression levels of MMP-14 and MMP-19 proteins in glioma tissues were both significantly higher (both P < 0.001) than those in non-neoplastic brain tissues according to the immunohistochemistry analysis, which was confirmed by the western blot analysis. Additionally, the overexpression of either MMP-14 or MMP-19 was significantly associated with the advanced WHO grade (both P = 0.02), the low Karnofsky performance score (KPS) (P = 0.008 and 0.01, respectively) and the poor overall survival (both P = 0.01). Moreover, the Multivariate Cox proportional-hazards regression analysis revealed that the increased expressions of MMP-14 and MMP-19 were both independent prognostic factors for poor overall survival (both P = 0.02). Furthermore, the co-expression of MMP-14 and MMP-19 was additively and more significantly (P = 0.006) associated with adverse prognosis in patients with gliomas than respective expression of MMP-14 and MMP-19.
These findings indicated for the first time that the co-expression of MMP-14 and MMP-19 is significantly correlated with prognosis in glioma patients, suggesting that the co-expression of these proteins may be used as both an early diagnostic and independent prognostic marker.
基质金属蛋白酶（MMP）-14 和 MMP-19 已被证明在人类脑胶质瘤的发展中发挥重要作用。然而，它们的预后价值尚不清楚。本研究旨在探讨 MMP-14 和 MMP-19 的共表达是否与人类脑胶质瘤的预后相关。
免疫组织化学和 Western blot 用于检测 128 例脑胶质瘤患者中 MMP-14 和 MMP-19 蛋白的表达。
根据免疫组织化学分析，胶质瘤组织中 MMP-14 和 MMP-19 蛋白的表达水平均明显高于非肿瘤性脑组织（均 P < 0.001），Western blot 分析也证实了这一点。此外，MMP-14 或 MMP-19 的过表达均与高级别 WHO 分级（均 P = 0.02）、较低的 Karnofsky 表现评分（KPS）（分别为 P = 0.008 和 0.01）和较差的总生存时间（均 P = 0.01）显著相关。此外，多变量 Cox 比例风险回归分析显示，MMP-14 和 MMP-19 的表达增加均是总生存时间不良的独立预后因素（均 P = 0.02）。此外，与 MMP-14 和 MMP-19 各自的表达相比，MMP-14 和 MMP-19 的共表达与胶质瘤患者的预后不良更显著相关（P = 0.006）。
这些发现首次表明，MMP-14 和 MMP-19 的共表达与胶质瘤患者的预后显著相关，提示这些蛋白的共表达可能被用作早期诊断和独立的预后标志物。
